BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 23287417)

  • 21. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia.
    Dvorak P; Dvorakova D; Doubek M; Faitova J; Pacholikova J; Hampl A; Mayer J
    Leukemia; 2003 Dec; 17(12):2418-25. PubMed ID: 14562121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
    Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
    Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
    Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
    J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis.
    Hosen N; Shirakata T; Nishida S; Yanagihara M; Tsuboi A; Kawakami M; Oji Y; Oka Y; Okabe M; Tan B; Sugiyama H; Weissman IL
    Leukemia; 2007 Aug; 21(8):1783-91. PubMed ID: 17525726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.
    Miething C; Feihl S; Mugler C; Grundler R; von Bubnoff N; Lordick F; Peschel C; Duyster J
    Leukemia; 2006 Apr; 20(4):650-7. PubMed ID: 16482207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
    Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
    Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).
    Chomel JC; Sorel N; Bonnet ML; Bertrand A; Brizard F; Saulnier PJ; Roy L; Guilhot F; Turhan AG
    Leuk Res; 2009 Apr; 33(4):551-5. PubMed ID: 18829107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia.
    Chomel JC; Sorel N; Bonnet ML; Bertrand A; Brizard F; Roy L; Guilhot F; Turhan AG
    Leuk Lymphoma; 2010 Nov; 51(11):2103-11. PubMed ID: 20929330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
    Chen M; Turhan AG; Ding H; Lin Q; Meng K; Jiang X
    Oncotarget; 2017 Jul; 8(27):43662-43677. PubMed ID: 28599273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
    Hayashi Y; Hirai H; Kamio N; Yao H; Yoshioka S; Miura Y; Ashihara E; Fujiyama Y; Tenen DG; Maekawa T
    Leukemia; 2013 Mar; 27(3):619-28. PubMed ID: 22948537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.
    Khorashad JS; Thelwell N; Milojkovic D; Marin D; Watson JA; Goldman JM; Apperley JF; Foroni L; Reid AG
    J Clin Pathol; 2008 Jul; 61(7):863-5. PubMed ID: 18587017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment.
    Zheng X; Oancea C; Henschler R; Moore MA; Ruthardt M
    PLoS One; 2009 Oct; 4(10):e7661. PubMed ID: 19876398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia.
    Jiang X; Stuible M; Chalandon Y; Li A; Chan WY; Eisterer W; Krystal G; Eaves A; Eaves C
    Blood; 2003 Oct; 102(8):2976-84. PubMed ID: 12829595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
    Watanabe T; Hotta C; Koizumi S; Miyashita K; Nakabayashi J; Kurotaki D; Sato GR; Yamamoto M; Nakazawa M; Fujita H; Sakai R; Fujisawa S; Nishiyama A; Ikezawa Z; Aihara M; Ishigatsubo Y; Tamura T
    Cancer Res; 2013 Nov; 73(22):6642-53. PubMed ID: 24242069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.
    Khateb M; Ruimi N; Khamisie H; Najajreh Y; Mian A; Metodieva A; Ruthardt M; Mahajna J
    BMC Cancer; 2012 Nov; 12():563. PubMed ID: 23186157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.
    Holm F; Hellqvist E; Mason CN; Ali SA; Delos-Santos N; Barrett CL; Chun HJ; Minden MD; Moore RA; Marra MA; Runza V; Frazer KA; Sadarangani A; Jamieson CH
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15444-9. PubMed ID: 26621726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells.
    Artus J; Zenych A; Simanic I; Desterke C; Clay D; Saïm S; Ijjeh Y; de Souza LEB; Coignard S; Bennaceur-Griscelli A; Turhan AG; Foudi A
    Exp Hematol; 2023 Aug; 124():22-35.e3. PubMed ID: 37331423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Dok-1 and Dok-2 in leukemia suppression.
    Niki M; Di Cristofano A; Zhao M; Honda H; Hirai H; Van Aelst L; Cordon-Cardo C; Pandolfi PP
    J Exp Med; 2004 Dec; 200(12):1689-95. PubMed ID: 15611295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
    Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.